Filing Flows › BioXcel Therapeutics (BTAIQ) › Q2 2026 › vs Q2 2025
BioXcel Therapeutics (BTAIQ) Q2 2026 vs Q2 2025 (year over year)
BioXcel Therapeutics's revenue rose $62K (+52%) from $120K in Q2 2025 to $182K in Q2 2026.
BioXcel Therapeutics, Q2 2026: revenue $182K (+52% year over year), net loss $14.7M, operating cash flow −$6.1M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $182K | $120K | $62K | +52% |
| Net loss | $14.7M | $19.2M | −$4.5M | -23% |
| Costs & expenses | $14.9M | $19.3M | −$4.4M | -23% |
| Operating costs | $10.4M | $16.0M | −$5.6M | -35% |
| Interest & other, net | $4.5M | $3.3M | $1.2M | +36% |
| Cost of revenue | $22K | $107K | −$85K | -79% |
| Research & development | $3.2M | $10.3M | −$7.1M | -69% |
| SG&A | $7.2M | $5.6M | $1.6M | +28% |
| Operating cash sources | $14.7M | $19.2M | −$4.5M | -23% |
| Depreciation | $18K | $75K | −$57K | -76% |
| Share-based compensation | $358K | $1.6M | −$1.2M | -77% |
| Working capital & other | $8.2M | $5.0M | $3.3M | +65% |
| Cash used in operations | $6.1M | $12.6M | −$6.5M | -52% |
| Net loss absorbed | $14.7M | $19.2M | −$4.5M | -23% |
Questions
How much did BioXcel Therapeutics's revenue grow year over year in Q2 2026?
BioXcel Therapeutics's revenue rose $62K (+52%) from $120K in Q2 2025 to $182K in Q2 2026.